HRAS
-
Official Full Name
v-Ha-ras Harvey rat sarcoma viral oncogene homolog
-
Overview
The 21 kDa guanine-nucleotide binding proteins (K-Ras, H-Ras and N-Ras) cycle between active (GTP-bound) and inactive (GDP-bound) forms. Receptor tyrosine kinases and G-protein-coupled receptors activate Ras, which then stimulates the Raf-MEK-MAPK pathway. GTPase-activating proteins (GAP) normally facilitate the inactivation of Ras. However, in 30% of human tumors, point mutations in Ras prevent the GAP-mediated inhibition of this pathway. The most common oncogenic Ras mutation found in tumors is Gly12 to Asp (G12D), which prevents Ras inactivation, possibly by increasing the overall rigidity of the protein. -
Synonyms
HRAS; v-Ha-ras Harvey rat sarcoma viral oncogene homolog; HRAS1; GTPase HRas; p21ras; H-Ras-1; p19 H-RasIDX protein; c-has/bas p21 protein; transforming protein p21; Ha-Ras1 proto-oncoprotein; c-ras-Ki-2 activated oncogene; GTP- and GDP-binding peptide B; transformation gene: oncogene HAMSV; Ras family small GTP binding protein H-Ras; CTLO; HAMSV; K-RAS; N-RAS; RASH1; C-H-RAS; H-RASIDX; C-BAS/HAS; C-HA-RAS1;
- Recombinant Proteins
- Cell & Tissue Lysates
- Protein Pre-coupled Magnetic Beads
- Chicken
- Human
- Mouse
- Rat
- Rhesus Macaque
- Bacterial
- E.coli
- HEK293
- HEK293T
- In Vitro Cell Free System
- Insect Cell
- Insect Cells
- Mammalian Cell
- Mammalian cells
- Wheat Germ
- C
- His
- Flag
- GST
- His (Fc)
- Avi
- Myc
- DDK
- MYC
- Myc|DDK
- N/A
- N
- Involved Pathway
- Protein Function
- Interacting Protein
- Other Resource
HRAS involved in several pathways and played different roles in them. We selected most pathways HRAS participated on our site, such as MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, which may be useful for your reference. Also, other proteins which involved in the same pathway with HRAS were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| MAPK signaling pathway | SOS1;RAC1B;CACNA2D3;PAK1;MRAS;CASP3B;FGF20B;ATF4B1;RAP1A |
| ErbB signaling pathway | AREG;PIK3R3A;PAK1;SHC4;ABL2;HBEGFB;KRAS;GAB1;MYCB |
| Ras signaling pathway | SHOC2;RGL1;TEK;RASA4;FGF2;STK4;PLA2G1B;GNGT1;NGFR |
| Rap signaling pathway | PFN1;ITGB1;FGF14;TLN1;KRAS;MAPK13;PARD3;MAPK3;PARD6B |
| Chemokine signaling pathway | CCR10;NFKBIA;CCR5;CCL15;PAK1;CCL13;PARD3;CCL8;CRKL |
| FoxO signaling pathway | PCK2;PIK3CB;G6PCA.1;IRS1;RBL2;STK4;MDM2;MAPK13;RAF1 |
| Sphingolipid signaling pathway | SGMS1;PIK3R3;PRKCE;PIK3CB;RHOA;GNAI3;MAPK8;PPP2R3A;PRKCG |
| Phospholipase D signaling pathway | PIK3CD;CXCR1;HRAS;INSR;SHC3;SOS1;AVPR1A;RALGDS;PRKCA |
| Endocytosis | RLN1;HSPA6;EPN2;VPS4A;CHMP6;PIP5K1AA;ARFGEF1;ARRB1;CBL |
| PIK-Akt signaling pathway | PDGFB;TNR;Ifna15;ITGA7;IFNA12;PHLPP1;YWHAZ;CRTC2;ITGAV |
| Axon guidance | HFE2;JAK3;DLG3;RGMA;AP2M1;EPHA3;AKAP9;ARPC1B;EPHA10 |
| VEGF signaling pathway | SHC2;NFATC2;CDC42L;PIK3CB;PTGS2A;PPP3CC;PPP3CCB;PIK3CD;VEGFAA |
| Focal adhesion | Itga10&Itgb1;COL6A2;ACTG1;CDC42L2;BCL2;ACTB2;MAPK6;HGF;VAV2 |
| Tight junction | PRKCBA;CLDN10A;EPB41L3A;F11R;RHOAB;MYL7;CLDND;MYL12.2;MAGI1B |
| Gap junction | KRAS;CSNK1DA;SOS1;GNAI2B;DRD2A;PLCB2;MAPK7;TUBB5;MAP2K2B |
| Signaling pathways regulating pluripotency of stem cells | WNT7B;GRB2;FZD2;ACVR2A;LHX5;MYF5;INHBA;DLX5;MAPK1 |
| Jak-STAT signaling pathway | PIK3CB;LIFRA;SOCS5B;AOX1;CRLF2;RAF1;AKT3A;IL22RA1;SOS1 |
| Natural killer cell mediated cytotoxicity | KIR3DL1;IFNA21;H60a;VAV2;IFNGR1;TNF;PTPN6;GM-CSF;IFNAR2 |
| T cell receptor signaling pathway | IL4;MAP2K2;PDCD1;GRAPA;CD247;PRKCQ;PIK3R1;PPP3R1;AKT1 |
| B cell receptor signaling pathway | IKBKG;ITK;RAC1;CRKL;ARPC2;VAV1;PIK3R1;PDK2B;AKT1 |
| Fc epsilon RI signaling pathway | PIK3CB;MAPK8;PLA2G4A;RAC3;VAV1;MAPK1;FYN;MAPK9;PLCG2 |
| Long-term potentiation | PRKCG;CALM1;RPS6KA3;CALM4;PRKACA;CAMK2D;PPP1CC;GNAQ;RPS6KA1 |
| Neurotrophin signaling pathway | Fasl;SHC1;CAMK2D;NTRK1;NFKB1;SH2B2;RAC1;CALML3;IRAK2 |
| Cholinergic synapse | ATF4;GNG13;KCNJ6;PRKCA;GNG11;ACHE;GNG2;CREB3L3;JAK2 |
| Serotonergic synapse | GNGT2;GNG5;HTR6;TPH1;HTR1F;GNB4;ITPR3;KRAS;GNG8 |
| Long-term depression | GRID2;GNAO1;PLA2G4D;MAPK1;ITPR3;PRKG1;GNAZ;PRKG2;PLCB3 |
| Regulation of actin cytoskeleton | FGF18A;PIK3CD;PIK3R5;PFN4;SLC9A1;ITGAV;WASLA;FGF16;ITGB1 |
| Insulin signaling pathway | FLOT2;CBLC;BRAF;CALM2;PIK3R3;RPS6;RHEB;PKLR;PHKB |
| GnRH signaling pathway | RAF1B;HRAS;CAMK2G1;CALM;MAPK7;GNA11;MAP2K4;MAPK8B;PLCB3 |
| Estrogen signaling pathway | HSPA1L;MAPK3;HSP90AA1;HSPA2;GNAS;PRKACA;CREB3L3;CALM4;MAP2K1 |
| Melanogenesis | FZD8A;WNT4A;EDNRB2;PLCB2;KITLGB;KRAS;TCF7L2;GNA15.1;WNT11B |
| Prolactin signaling pathway | ELF5;PIK3CD;CCND1;SIRPA;AKT2;KRAS;SOS1;MAPK13;INS1 |
| Thyroid hormone signaling pathway | ACTB;TBC1D4;ATP1A4;ATP1A1;PLN;MAPK3;MED30;PRKACB;SIN3A |
| Oxytocin signaling pathway | RYR1;CACNA2D4;CAMKK1;CACNB4;HRAS;PPP1CB;PPP1R12C;CALM1;ITPR1 |
| Alcoholism | CAMK4;CREB3L4;H3F3A;GNAO1;H2AFY;SHC3;HIST1H2BF;HIST1H4K;HIST1H3H |
| Hepatitis C | BAD;TYK2;IRF9;IFNA14;PPP2R2C;GSK3B;CLDN23;BRAF;RAF1 |
| Hepatitis B | PIK3CA;KRAS;PIK3CG;PCNA;CXCL8;PIK3R5;MAVS;NFATC4;NFATC3 |
| HTLV-I infection | CDC16;IKBKB;CANX;ATF1;HLA-G;BCL2L1;LTBR;NFYB;TLN1 |
| Pathways in cancer | FGF19;BIRC7;PIAS2;GNG2;KRAS;PTGER3;TGFB3;IGF1R;GLI3 |
| Viral carcinogenesis | HIST1H2BG;RELA;NFKB2;LTBR;H2-Q10;SRF;YWHAH;STAT5B;RHOA |
| Proteoglycans in cancer | WNT6;ERBB4;FZD3;CAV3;TLR4;ITGB1;WNT2B;PLCG1;WNT9B |
| MicroRNAs in cancer | PLAU;TRP63;BMF;MET;RPS6KA5;BCL2;NOTCH3;PIM1;ITGB3 |
| Renal cell carcinoma | HGF;RAF1;EGLN1;PAK3;CDC42;PAK6;ETS1;PAK1;PIK3R2 |
| Endometrial cancer | CASP9;NRAS;TP53;PIK3R1;KRAS;PIK3R5;PIK3CA;ELK1;ERBB2 |
| Glioma | PIK3CA;PTEN;SHC4;HRAS;TRP53;IGF1;NRAS;RB1;SOS1 |
| Prostate cancer | IKBKG;PIK3CD;CCND1;NFKB1;PIK3CB;ATF4;PDGFB;MTOR;BAD |
| Thyroid cancer | CCND1;MAP2K1;CCDC6;NCOA4;NRAS;NTRK1;PPARG;PAX8;TCF7 |
| Melanoma | BRAF;PDGFD;MITF;FGF19;BAD;FGF5;FGF6;FGFR1;FGF4 |
| Bladder cancer | RB1;E2F1;TP53;TYMP;E2F2;DAPK1;CDK4;MMP2;MMP1 |
| Chronic myeloid leukemia | TRP53;PIK3R5;HDAC2;STAT5A;CDK6;AKT2;SMAD4;PIK3CB;CBLC |
| Acute myeloid leukemia | KRAS;AKT2;BRAF;MTOR;PIK3CA;RAF1;PIK3CB;STAT5A;TCF7L2 |
| Non-small cell lung cancer | RB1;RXRB;PIK3R5;RARB;FOXO3;PIK3R3;CCND1;RXRG;MAP2K2 |
| Central carbon metabolism in cancer | PIK3R2;SLC2A1;PTEN;HK1;PKM;AKT1;SLC1A5;MET;SLC16A3 |
| Choline metabolism in cancer | TSC1;SP1;WAS;PLD2;PPAP2A;MAPK3;LYPLA1;PIK3CA;SLC5A7 |
HRAS has several biochemical functions, for example, GTP binding, GTPase activity, protein C-terminus binding. Some of the functions are cooperated with other proteins, some of the functions could acted by HRAS itself. We selected most functions HRAS had, and list some proteins which have the same functions with HRAS. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| GTP binding | GBP2;RRAGCA;RAB42B;SRL;RAB26;ATL3;ARF4B;RAB27B;ARL3 |
| GTPase activity | RAB11B;EIF2S3Y;NOA1;TUBA8L2;GNA15;GNAI2;OPA1;IIGP1;GNAI1 |
| protein C-terminus binding | TRP53;PFKM;HSPB7;MLLT4;ERCC6;LIG4;TNNI3K;SIAH1A;ERCC4 |
| protein binding | SHPRH;ATF7;HOXA5;APOA4;MYL6;UNG;GPANK1;CCDC106;RAB26 |
HRAS has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with HRAS here. Most of them are supplied by our site. Hope this information will be useful for your research of HRAS.
RAF1; SOS1
Research Area
Related articles
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewWith their meticulous documentation and support, I am confident that my utilization of the HRAS protein in clinical trials will meet all necessary regulations and guidelines.
Their comprehensive certificates of analysis and safety data sheets serve as testaments to their commitment to ensuring the safety and integrity of their products.
Their ability to accommodate the requirements of large-scale experiments and guarantee a steady supply streamlines my research operations, eliminating any concerns related to prospective shortages.
Q&As (5)
Ask a questionResearch is ongoing, but there are emerging targeted therapies designed to address HRAS-related cancers.
Yes, genetic testing can identify HRAS mutations, aiding in the diagnosis and prognosis of certain disorders.
Yes, there is growing interest in exploring HRAS as a therapeutic target for non-cancerous diseases, such as cardiovascular disorders.
HRAS status can impact the response to certain cancer treatments, affecting the efficacy of targeted therapies and chemotherapy.
HRAS regulates the cell cycle by influencing the transition between different phases, ensuring proper cell division.
Ask a Question for All HRAS Products
Required fields are marked with *
My Review for All HRAS Products
Required fields are marked with *
